Great risk reward.. Bio stocks can go long periods without any news. By year end or Q1 phase 2a data should be released and hopefully US patents issued.
Just my guess, but I would think the safety profile is excellent otherwise NIH would have stopped the study. Study is complete I believe and now it is just assembling data.
Patience here...Remember what AGN paid for the Naurex drug which was intravenous.
News 
Market Data 
Discover 
